Page 763 - Clinical Application of Mechanical Ventilation
P. 763
Index 729
transcutaneous blood gas, 265–266 Neuromuscular blockade, evaluation of, 437–438, 438t
vital signs, 243–246 Neuromuscular blocking agents, 431–438
blood pressure, 243–244 adverse effects of, 436–437, 437t
heart rate, 243 characteristics of, 433
respiratory frequency, 244–245 depolarizing, 433, 434t
temperature, 245–246 factors affecting, 433–436
Monoamine oxidase (MAO), 424, 425 in hyperbaric condition, 597
Monoplace hyperbaric chamber, 599 mechanism of action, 432–433, 432f
Montomery and Ventrach speaking valve, 177 nondepolarizing, 433, 434t
Morphine sulfate, 472–473, 473t Newport HT50, 595
mPaw. See Mean airway pressure (mPaw) Nitric acid, 453
Multiplace hyperbaric chamber, 596, 601t Nitric oxide, 452–454
Muscle atrophy, 99 Nitrous acid, 453
Muscle contraction, 434–435 Nondepolarizing agents, 433, 434t
Muscle fatigue, 41, 41t Noninvasive positive pressure ventilation (NPPV),
Myasthenia gravis case study, 656–660 192–211
Mycobacterium tuberculosis, 476 common interfaces for, 198–203
Myoclonus, 445 defined, 193
indications and contraindications, 198t
N physiologic effects of, 194
terminology, 194, 195t
Naloxone, 444t uses of, 195–198
Narcan, 444t Non-pressure-compensated ventilators, 604
Narcotics, 444t, 445t Norcuron, 434t, 437t
Nasal CPAP (N-CPAP), 552–553 Normal arterial pressure, 279, 279f
Nasal intubation, 154, 155, 163, 166t NPPV. See Noninvasive positive pressure ventilation
Nasal mask, 198, 199f, 199t (NPPV)
Nasal pillows, 200–201, 201f, 202f Nutrition
Nasopharyngeal airway, 128–130, 130f low-carbohydrate high-fat diet, 406–407
insertion of, 129, 130f overfeeding, 406t
selection of, 129 phosphate supplement, 407
size chart for, 129t and positive pressure ventilation, 40–43
Natural disasters, 589–590 total caloric requirements, 407
Negative pressure ventilation, 59f, 82–84, 194 total parenteral, 42–43
Negative pressure ventilator, 58 undernutrition, 405, 406t
Neonatal mechanical ventilation, 544–579 and work of breathing, 42–43
basic principles of, 553–555 Nutritional support, 41–42
extracorporeal membrane oxygenation, 568–572
high frequency ventilation, 558–566 O
indications for, 546, 555–556, 556t
initial ventilator settings, 556–558 Obstructive sleep apnea (OSA), 196–197, 196t
initiation of, 555–558 Oliguria, 253
intubation, 546–548 One-chamber drainage system, 466–467, 467f
nasal CPAP, 552–553 Operating modes, 80–124
other methods of, 566–568 adaptive pressure control, 108
surfactant replacement therapy, 548–551 adaptive support ventilation, 104–105
Nerve agents, 590 airway pressure release ventilation, 111–112
Neurally adjusted ventilatory assist (NAVA), 115 assist/control, 94–96
Neuroleptic malignant syndrome, 451 automatic tube compensation, 115
Neurologic changes automode, 108
and hyperventilation, 43, 43t bilevel positive airway pressure, 91–92
indicators of, 44 biphasic positive airway pressure, 112–113
Neurologic dysfunction, 19t closed-loop system, 86
Copyright 2013 Cengage Learning. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s).
Editorial review has deemed that any suppressed content does not materially affect the overall learning experience. Cengage Learning reserves the right to remove additional content at any time if subsequent rights restrictions require it.
